LTR Pharma Ltd
LTP
Company Profile
Business description
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men’s health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
Contact
9A/204 Alice Street
BrisbaneQLD4000
AUST: +61 1800519711
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Our top ASX picks in every sector
These companies are our top choices for investors wanting to boost Aussie exposure.
stocks
Potentially catastrophic ruling for ASX company
We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks
4 charts on Nvidia’s record $4 trillion market cap
Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,875.30 | 60.00 | 0.68% |
| CAC 40 | 7,766.21 | 41.96 | -0.54% |
| DAX 40 | 24,060.29 | 100.35 | -0.42% |
| Dow JONES (US) | 44,023.29 | 436.36 | -0.98% |
| FTSE 100 | 8,938.32 | 59.74 | -0.66% |
| HKSE | 24,590.12 | 386.80 | 1.60% |
| NASDAQ | 20,677.80 | 37.47 | 0.18% |
| Nikkei 225 | 39,678.02 | 218.40 | 0.55% |
| NZX 50 Index | 12,689.63 | 10.94 | 0.09% |
| S&P 500 | 6,243.76 | 24.80 | -0.40% |
| S&P/ASX 200 | 8,630.30 | 59.90 | 0.70% |
| SSE Composite Index | 3,505.00 | 14.65 | -0.42% |